References
- 1. Stanton AL, Danoff-Burg S, Huggins M. The first year after breast cancer diagnosis: hope and coping strategies as predictors of adjustment. Psychooncology 2002; 11: 93-102.
- 2. Ozalp E, Soygu H, Cankurtaran E, Turhan L, Akbyk D, Geyik P. Psychiatric morbidity and its screening in Turkish women with breast cancer: a comparison between the HADS and SCID tests. Psychooncology 2008; 17: 668-75. Lueboonthavatchai P. Prevalence and psychosocial factors of anxiety and depression in breast cancer patients. J Med Assoc Thai 2007; 90: 2164-74.
- 3. Boehmke MM, Dickerson SS. The diagnosis of breast cancer: transition from health to illness. Oncol Nurs Forum 2006, 33: 1121-7.
- 4. Fertig DL. Depression in patients with breast cancer: prevalence, diagnosis, and treatment. Breast J 1997; 5: 292-302.
- 5. Holland JC, Mastrovito R. Psychologic adaptation to breast cancer. Cancer. 1980; 46(4 Suppl): 1045-52.
- 6. Akechi T, Okuyama T, Imoto S, Yamawaki S, Uchitomi Y. Biomedical and psychosocial determinants of psychiatric morbidity among postoperative ambulatory breast cancer patients. Breast Cancer Res Treat 2001; 65: 195-202.
- 7. Matsuoka Y, Nakano T, Inagaki M, Sugawara Y, Akechi T, Imoto S, et al. Cancer-related intrusive throughs as an indicator of poor psychological adjustment at 3 or more years after breast surgery: a preliminary study. Breast Cancer Res Treat 2002; 76: 117-24.
- 8. Cordova MJ, Giese-Davis J, Golant M, Kronnenwetter C, Chang V, Mc Farlin S, et al. Mood disturbance in community cancer support groups. The role of emotional suppression and fighting spirit. J Psychosomatic Res 2003; 55: 461-7.
- 9. Grassi L, Buda P, Cavana L, Annunziata MA, Torta R, Varetto A. Styles of coping with cancer: The Italian version of the Mini-Mental Adjustment to Cancer (Mini-Mac) scale. Psychooncology 2005; 14: 115-24.
- 10. Grassi L, Travado L, Moncayo FLG, Sabato S, Rossi E and the SEPOS group. Psychosocial morbidity and its correlates in cancer patients of the Mediterranean area: findings from the Southern European Psycho-Oncology Study. J Affect Disord 2004; 83: 243-8.
- 11. Bloom JR, Stewart SL, Johnston M, Banks P, Fobair P. Sources of support and the physical and mental well being of young women with breast cancer. Soc Sci Med 2001; 53: 1513-24.
- 12. Greer S, Morris T, Pettingale KW. Psychological response to breast cancer: effect on outcome. Lancet 1979; 2: 785-7.
- 13. Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet 1999; 354: 1331-6.
- 14. Erculj N, Kovac V, Hmeljak J, Dolzan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol 2012; 23: 461-7.
- 15. Erčulj N, Kovač V, Hmeljak J, Franko A, Dodič-Fikfak M, Dolžan V. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet Genomics 2012; 22: 58-68.
- 16. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-9.
- 17. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31.
- 18. Plesnicar A, Golicnik M, Fazarinc IK, Kralj B, Kovac V, Plesnicar BK. Attitudes of midwifery students towards teaching brast-self examination. Radiol Oncol 2010; 44: 52-6.
- 19. Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer - prognostic factors and survival. Radiol Oncol 2011; 45: 46-52.
- 20. Andersen B, William B, Farrar WB, Golden-Kreutz D, Kutz LA, Courtney ME, et al. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998; 90: 30-6.
- 21. Zalsman G, Huang Y, Oquendo MA, Burke AK, Hu X, Brent DA, et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry 2006; 163: 1588-93.
- 22. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815-26.
- 23. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-70.
- 24. Garcia-Cebrian A, Bauer M, Montejo AL, Dantchev N, Demyttenaere K, Gandhi P, et al. Factors influencing depression endpoints research (FINDER): Study design and population characteristics. European Psychiatry 2008; 23: 57-65.
- 25. Gelernter J, Kranzler H, Cubbels JF. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 1997; 101: 243-6.
- 26. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2010; 301: 2462-71.
- 27. Munafò MR, Freimer NB, Ng W, Ophoff R, Veijola J, Miettunen J, et al. 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B 2009; 150: 271-81.
- 28. Middeldorp CM, de Geus EJ, Willemsen G, Hottenga JJ, Slagboom PE, Boomsma DI. The serotonin transporter gene length polymorphism (5-HTTLPR) and life events: no evidence for an interaction effect on neuroticism and anxious depressive symptoms. Twin Res Hum Gen 2010; 13: 544-9.
- 29. Karg K, Burmeister M, Shedden K, Sen S. The Serotonin Transporter Promoter Variant (5-HTTLPR), Stress, and Depression Meta-analysis Revisited: Evidence of Genetic Moderation. Arch Gen Psychiat 2011; 68: 444-54.
- 30. Grassi L, Rossi E, Cobianchi M, Aguiari L, Capozzo MA, et al. Depression and serotonin transporter (5-HTTLPR) polymorphism in breast cancer patients. J Affect Disord 2010; 124: 346-50.
- 31. Kash KM, Mago R, Kunkel E. Psychosocial oncology: supportive care for the cancer patients. Semin Oncol 2004; 32: 211-8.
- 32. Ho SM, Fung WK, Chan CL, Watson M, Tsui YK. Psychometric properties of the Chinese version of the Mini-Mental Adjustment to Cancer (MINIMAC) scale. Psychooncology 2003; 12: 547-56.
- 33. Anagnostopoulos F, Kolokotroni P, Spanea E, Chryssochoou M. The minimental adjustment to cancer (mini-MAC) scale: construct validation with a Greek sample of breast cancer patients. Psychooncology 2006; 15: 79-89.
- 34. Capozzo MA, Martinis E, Pellis G, Giraldi T. An early structured psychoeducational intervention in breast cancer patients: results from a feasibility study. Cancer Nurs 2010; 33: 228-34.
- 35. Fawzy FI, Fawzy NW. A structured psychoeducational intervention for cancer patients. Gen Hosp Psychiatry 1994; 16: 149-52.
- 36. Carver CS, Pozo C, Harris SD. How coping mediates the effect of optimism on distress: A study of women with early stage breast cancer. J Pers Soc Psychol 1993; 65: 375-90.
- 37. Osowiecki D, Compas BE. Psychological adjustment to cancer: Control beliefs and coping in adult cancer patients. Cog Ther Res 1998; 22: 483-99.
- 38. Stanton AL, Danoff-Burg S, Cameron CL. Emotionally expressive coping predicts psychological and physical adjustment to breast cancer. J Consul Clin Psychol 2000; 68: 875-82.
- 39. Roth S, Cohen LJ. Approach, avoidance, and coping with stress. Am Psychol 1986; 41: 813-9.
- 40. Fukui S, Kugaya A, Okamura H, Kamiya M, Koike M, Nakanishi T, et al. A psychosocial group intervention for Japanese women with primary breast cancer: a randomized controlled trial. Cancer 2000; 89: 1026-36.
- 41. Weis J. Support groups for cancer patients. Support Care Cancer 2003; 11: 763-8.
- 42. Kissane D, Bloch S, Smith GC, Miach P. Cognitive-existential group psychotherapy for women with primary breast cancer: a randomised controlled trial. Psychooncology 2003; 12: 532-46.
- 43. Maeda T, Kurihara H, Morishima I, Munakata T. The effect of psychological intervention on personality change, coping, and psychological distress of Japanese primary breast cancer patients. Cancer Nurs 2008; 31: 27-35.
- 44. Smits K, Smits L, Peeters F, Schouten J, Janssen R, Smeets H, et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharm 2007; 22: 137-43.
- 45. Schillani G, Capozzo MA, Aguglia E, De Vanna, M, Grassi L, Conte MA, et al. 5-HTTLPR polymorphism of serotonin transporter and effects of sertraline in terminally ill cancer patients: report of eleven cases. Tumori 2008; 94: 563-7.
- 46. Capozzo MA, Schillani G, Aguglia E, De Vanna M, Grassi L, Conte MA, et al. Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: report of twenty-one cases. Tumori 2009; 95: 479-83.
- 47. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatr 2010; 15: 473-500.
- 48. Bandelow B, Andersen HF, Dolberg OT. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety 2007; 24: 53-6.
- 49. Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Turhan L, Alkis N. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer 2008; 16: 1291-8.
- 50. Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011; 12: 570-7.
- 51. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340: c693.
- 52. In brief: Tamoxifen and SSRI interaction. Med Lett Drugs Ther. 2009; 51(1314): 45.